$53.71
0.07% today
Nasdaq, Aug 12, 04:46 pm CET
ISIN
US74366E1029
Symbol
PTGX

Protagonist Therapeutics, Inc. Stock price

$53.75
+0.75 1.42% 1M
+16.76 45.31% 6M
+15.15 39.25% YTD
+13.15 32.39% 1Y
+43.35 416.83% 3Y
+36.79 216.92% 5Y
+42.05 359.40% 10Y
+42.05 359.40% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+2.68 5.25%

Key metrics

Basic
Market capitalization
$3.3b
Enterprise Value
$2.8b
Net debt
positive
Cash
$570.5m
Shares outstanding
62.1m
Valuation (TTM | estimate)
P/E
66.4 | negative
P/S
16.0 | 40.3
EV/Sales
13.3 | 33.4
EV/FCF
74.8
P/B
5.0
Financial Health
Equity Ratio
90.7%
Return on Equity
40.8%
ROCE
3.5%
ROIC
17.9%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$209.2m | $82.9m
EBITDA
$25.7m | $-146.1m
EBIT
$24.0m | $-136.7m
Net Income
$52.0m | $-123.1m
Free Cash Flow
$37.1m
Growth (TTM | estimate)
Revenue
-34.5% | -80.9%
EBITDA
-83.4% | -157.2%
EBIT
-84.3% | -154.1%
Net Income
-69.4% | -144.7%
Free Cash Flow
-83.9%
Margin (TTM | estimate)
Gross
-
EBITDA
12.3% | -176.3%
EBIT
11.5%
Net
24.9% | -148.5%
Free Cash Flow
17.7%
More
EPS
$0.8
FCF per Share
$0.6
Short interest
12.0%
Employees
126
Rev per Employee
$3.5m
Show more

Is Protagonist Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Protagonist Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Protagonist Therapeutics, Inc. forecast:

16x Buy
89%
2x Hold
11%

Analyst Opinions

18 Analysts have issued a Protagonist Therapeutics, Inc. forecast:

Buy
89%
Hold
11%

Financial data from Protagonist Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
209 209
34% 34%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 41 41
3% 3%
20%
- Research and Development Expense 144 144
13% 13%
69%
26 26
83% 83%
12%
- Depreciation and Amortization 1.73 1.73
21% 21%
1%
EBIT (Operating Income) EBIT 24 24
84% 84%
11%
Net Profit 52 52
69% 69%
25%

In millions USD.

Don't miss a Thing! We will send you all news about Protagonist Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Protagonist Therapeutics, Inc. Stock News

Neutral
The Motley Fool
5 days ago
Protagonist (PTGX) Q2 Revenue Falls 26%
Neutral
Accesswire
6 days ago
NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO) submitted to U.S. FDA in July ANTHEM Phase 2b trial data of icotrokinra in ulcerative colitis scheduled for an oral presentation at the 33rd United European Gastroenterology Week (UEGW) on October 7th Phase 3 VERIFY trial data set of rusfertide in polycythemia...
Neutral
Investors Business Daily
about one month ago
Protagonist Therapeutics is taking aim directly at Eli Lilly's obesity treatment with a newly announced drug that uses the same mechanism.
More Protagonist Therapeutics, Inc. News

Company Profile

Protagonist Therapeutics, Inc. engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Head office United States
CEO Dinesh Patel
Employees 126
Founded 2006
Website www.protagonist-inc.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today